International Journal of Antimicrobial Agents
Volume 36, Issue 3 , Pages 197-204 , September 2010

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia

  • Ronald N. Jones

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Ste A, North Liberty, IA 52317, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 319 665 3370; fax: +1 319 665 3371.
    • ,
  • Michael R. Jacobs

      Affiliations

    • Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, OH, USA
    • ,
  • Helio S. Sader

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Ste A, North Liberty, IA 52317, USA

References 

  1. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med. 1995;333:1618–1624
  2. Jacobs MR. Antimicrobial-resistant Streptococcus pneumoniae: trends and management. Expert Rev Anti Infect Ther. 2008;6:619–635
  3. National Center for Health Statistics. Health, United States; 2008, with special feature on health of young adults. http://www.cdc.gov/nchs/data/hus/hus08.pdf [accessed 1 May 2009].
  4. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005;128:3854–3862[Erratum in: Chest 2006;129:831]
  5. Mandell LA, Wunderink RG, Anzueto A Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl. 2):S27–S72
  6. US Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report: Emerging Infections Program Network, Streptococcus pneumoniae, 2007. Atlanta, GA: CDC; 2008. http://www.cdc.gov/abcs/reports-findings/survreports/spneu07.pdf [accessed 14 May 2010].
  7. Jacobs MR. Streptococcus pneumoniae: epidemiology and patterns of resistance. Am J Med. 2004;117(Suppl. 3A):3S–15S
  8. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis. JAMA. 1996;275:134–141
  9. Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health. 2000;90:223–229
  10. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Hib and Pneumococcal Global Burden of Disease Study Team Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374:893–902
  11. Rodriguez A, Lisboa T, Blot S, Martin-Loeches I, Solé-Violan J, De Mendoza D, et al. Community-Acquired Pneumonia Intensive Care Units (CAPUCI) Study Investigators Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intensive Care Med. 2009;35:430–438
  12. De Graeve D, Beutels P. Economic aspects of pneumococcal pneumonia: a review of the literature. Pharmacoeconomics. 2004;22:719–740
  13. Sun HK, Nicolau DP, Kuti JL. Resource utilization of adults admitted to a large urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae. Chest. 2006;130:807–814
  14. Agency for Healthcare Research and Quality. Improving treatment decisions for patients with community-acquired pneumonia. Rockville, MD: AHRQ; 2002. http://www.ahrq.gov/clinic/pneumonia/pneumonia.htm#fn1 [accessed 15 May 2009].
  15. Daneman N, Low DE, McGeer A, Green KA, Fisman DN. At the threshold: defining clinically meaningful resistance thresholds for antibiotic choice in community-acquired pneumonia. Clin Infect Dis. 2008;46:1131–1138
  16. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet. 2006;368:1495–1502
  17. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MCC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol. 2007;45:1225–1233
  18. Park IH, Park S, Hollingshead SK, Nahm MH. Genetic basis for the new pneumococcal serotype, 6C. Infect Immun. 2007;75:4482–4489
  19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twentieth informational supplement. Document M100-S20. Wayne, PA: CLSI; 2010.
  20. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis. 2009;48:1596–1600
  21. Jacobs MR, Bajaksouzian S, Windau A, Good C, Biek D, Critchley IA, et al. Activity of ceftaroline against emerging serotypes of Streptococcus pneumoniae. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12–14 September 2009, San Francisco, CA. Washington, DC: ASM Press; 2009;
  22. Lynch JP, Zhanel GG. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin Respir Crit Care Med. 2005;26:575–616
  23. Widdowson CA, Klugman KP. Molecular mechanisms of resistance to commonly used non-β-lactam drugs in Streptococcus pneumoniae. Semin Respir Infect. 1999;14:255–268
  24. Davies TA, Shang W, Bush K. Activities of ceftobiprole and other β-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob Agents Chemother. 2006;50:2530–2532
  25. Hakenbeck R, Kaminski K, König A, van der Linden M, Paik J, Reichmann P, et al. Penicillin-binding proteins in β-lactam-resistant Streptococcus pneumoniae. Microb Drug Resist. 1999;5:91–99
  26. Deeks SL, Palacio R, Ruvinsky R, Kertesz DA, Hortal M, Rossi A, et al. The Streptococcus pneumoniae Working Group Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. Pediatrics. 1999;103:409–413
  27. Pallares R, Liňares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995;333:474–480
  28. Pallares R, Capdevila O, Liňares J, Grau I, Onaga H, Tubau F, et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med. 2002;113:120–126
  29. Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, et al. International Pneumococcal Study Group An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003;37:230–237
  30. Farrell DJ, Couturier C, Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT Year 5 (2003–2004). Int J Antimicrob Agents. 2008;31:245–249
  31. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1–4. Ann Clin Microbiol Antimicrob. 2008;7:1
  32. Janoir C, Zeller V, Kitzis MD, Moreau NJ, Gutmann L. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother. 1996;40:2760–2764
  33. Pletz M, McGee L, Jorgensen J, Beall B, Facklam RR, Whitney CG, et al. Active Bacterial Care Surveillance Team Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother. 2004;48:3491–3497
  34. Jacobs MR, Koornhof HJ, Robins-Browne RM, Stevenson CM, Vermaak ZA, Freiman I, et al. Emergence of multiply resistant pneumococci. N Engl J Med. 1978;299:735–740
  35. Doern GV, Brueggemann A, Holley HP, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:1208–1213
  36. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Beekmann SE, Doern GV. Changing epidemiology of antimicrobial-resistant Streptococcus pneumoniae in the United States, 2004–2005. Clin Infect Dis. 2009;48:e23–e33
  37. Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs. 2007;67:2355–2382
  38. Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis. 2008;8:785–795
  39. Centers for Disease Control and Prevention (CDC). Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction: eight states, 1998–2005. MMWR Morb Mortal Wkly Rep 2008;57:144–8.
  40. Shields B. Prevnar (heptavalent pneumococcal conjugate vaccine): disease prevention in infants and children. J Pediatr Health Care. 2001;15:203–210
  41. Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog. 2007;3:e168
  42. Gertz RE, Li Z, Pimenta FC, Jackson D, Juni BA, Lynfield R, et al. Active Bacterial Care Surveillance Team Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J Infect Dis. 2010;201:770–775
  43. Mera R, Miller LA, Fritsche TR, Jones RN. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist. 2008;14:101–107
  44. Jacobs MR, Bajaksouzian S, Bonomo RA, Good CE, Windau AR, Hujer AM, et al. Occurrence, distribution, and origins of Streptococcus pneumoniae serotype 6C, a recently recognized serotype. J Clin Microbiol. 2009;47:64–72
  45. Nahm MH, Lin J, Finkelstein JA, Pelton SI. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis. 2009;199:320–325
  46. Critchley IA, Jacobs MR, Brown SD, Traczewski MM, Tillotson GS, Janjic N. Prevalence of serotype 19A Streptococcus pneumoniae among isolates from US children in 2005–2006 and activity of faropenem. Antimicrob Agents Chemother. 2008;52:2639–2643
  47. Jacobs MR, Good CE, Bajaksouzian S, Windau AR. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis. 2008;47:1388–1395
  48. Messina AF, Katz-Gaynor K, Barton T, Ahmad N, Ghaffar F, Rasko D, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J. 2007;26:461–467
  49. Reynolds TA. Update on emerging infections: news from the Centers for Disease Control and Prevention. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae—Massachusetts, 2001–2006. Ann Emerg Med. 2008;51:312–315
  50. Moore MR, Gertz RE, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197:1016–1027
  51. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN Alexander Project Group. The Alexander Project 1998–2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother. 2003;52:229–246
  52. Castanheira M, Gales AC, Pignatari ACC, Jones RN, Sader HS. Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: report from the SENTRY antimicrobial surveillance program (1998–2004). Microb Drug Resist. 2006;12:91–98
  53. Deshpande LM, Sader HS, Debbia E, Nicoletti G, Fadda G, Jones RN. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001–2004). Diagn Microbiol Infect Dis. 2006;54:157–164
  54. Fluit AC, Schmitz FJ, Jones ME, Acar J, Gupta R, Verhoef J, et al. SENTRY Participants Group Antimicrobial resistance among community-acquired pneumonia isolates in Europe: first results from the SENTRY Antimicrobial Surveillance Program 1997. Int J Infect Dis. 1999;3:153–156
  55. Johnson DM, Stilwell MG, Fritsche TR, Jones RN. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999–2003). Diagn Microbiol Infect Dis. 2006;56:69–74
  56. Ishida T, Maniwa K, Kagioka H, Hirabayashi M, Onaru K, Tomioka H, et al. Antimicrobial susceptibilities of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Japan. Respirology. 2008;13:240–246
  57. Song JH, Oh WS, Kang CI, Chung DR, Peck KR, Ko KS, et al. Asian Network for Surveillance of Resistant Pathogens Study Group Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian Network for Surveillance of Resistant Pathogens. Int J Antimicrob Agents. 2008;31:107–114
  58. European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2008. Bilthoven, The Netherlands: National Institute for Public Health and the Environment; 2009.
  59. van de Sande-Bruinsma N, Grundmann H, Verloo D, Tiemersma E, Monen J, Goossens H, et al. European Antimicrobial Consumption Projects Group Antimicrobial drug use and resistance in Europe. Emerg Infect Dis. 2008;14:1722–1730
  60. Jacobs MR, Good CE, Beall B, Bajaksouzian S, Windau AR, Whitney CG. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J Clin Microbiol. 2008;46:982–990
  61. Jacobs MR, Good CE, Windau AR, Bajaksouzian S, Biek D, Critchley IA, et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the USA. Antimicrob Agents Chemother. 2010;54:2716–2719
  62. European Committee on Antimicrobial Susceptibility Testing. EUCAST; 2009. http://www.eucast.org/clinical_breakpoints/ [accessed 14 May 2010].
  63. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl. 3):iii1–iii55
  64. Weiss K, Low DE, Cortes L, Beaupre A, Gauthier R, Gregoire P, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J. 2004;11:589–593
  65. Blasi F, Farrell DJ, Dubreuil L. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin study year 5 (2003–2004). Diagn Microbiol Infect Dis. 2009;63:302–308
  66. Fogarty CM, Patel TC, Dunbar LM, Leroy BP. Efficacy and safety of telithromycin 800mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study. BMC Infect Dis. 2005;5:43–51
  67. Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. J Antimicrob Chemother. 2003;51:947–955
  68. Clay KD, Hanson JS, Pope SD, Rissmiller RW, Purdum PP, Banks PM. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med. 2006;144:415–420
  69. Fritsche TR, Sader HS, Jones RN. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006). Diagn Microbiol Infect Dis. 2008;61:86–95
  70. Fenoll A, Aguilar L, Robledo O, Giménez MJ, Granizo JJ, Biek D, et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother. 2008;52:4209–4210
  71. Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52:3398–3407
  72. McGee L, Biek D, Ge Y, Klugman M, du Plessis M, Smith AM, et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2009;53:552–556
  73. Morrissey I, Ge Y, Janes R. Activity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumonia. Int J Antimicrob Agents. 2009;33:515–519
  74. Patel SN, Pillai DR, Pong-Porter S, McGeer A, Green K, Low DE. In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. J Antimicrob Chemother. 2009;64:659–660
  75. Panagiotidis G, Bäckström T, Asker-Hagelberg C, Jandourek A, Weintraub A, Nord CE. Effect of ceftaroline on normal human intestinal microflora. Antimicrob Agents Chemother. 2010;54:1811–1814
  76. McKeage K, Keating GM. Tigecycline: in community-acquired pneumonia. Drugs. 2008;68:2633–2644
  77. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, et al. 308 Study Group Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis. 2009;63:52–61
  78. Dartois N, Castaing N, Gandjini H, Cooper A Tigecycline 313 Study Group. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J Chemother. 2008;20(Suppl. 1):28–35
  79. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, et al. 308 and 313 Study Groups Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis. 2008;61:329–338

PII: S0924-8579(10)00201-3

doi: 10.1016/j.ijantimicag.2010.04.013

International Journal of Antimicrobial Agents
Volume 36, Issue 3 , Pages 197-204 , September 2010

Article Tools

* Image Usage & Resolution